An observational study in Rare Disease With Poor Outcome, sponsored by Central Hospital, Nancy, France. Status unknown. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-04-26.
Sponsored by Central Hospital, Nancy, France · Observational
Primary Central Nervous System Lymphoma (PCNSL) have a specific mutational profile in comparison to systemic diffuse large cells lymphoma (DLBCLs) that can be related to the expression of immunohistochemical markers as cyclon, NPM1, CD30, and P53 which could be predictive factor for prognosis and/or chemotherapy response. The main objective of this study is to identify new prognostic factors and new potential therapeutic targets.
The secondary objectives are to correlate the histological, the radiological and the clinical's informations of these patients.
203 studies on the registry are indexed under Rare Diseases; 112 are open to participants now.
This study's planned enrollment of 94 is below the median of 200 across 125 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults' immunocompetent patients treated at the University Hospital of Nancy are included if they had a DLBCL's PCNSL diagnosed between January 2011 and December 2019, without regard to the clinical outcome.. All the patients are included in the LOC network database (Lymphomes oculo-cerebraux) and had given their written consent for the use of their samples for studies. Biological and clinical data will be collected for each patient from original medical charts.
Exclusion Criteria:
correlation between the survival and the expression of Cyclon, NPM1 and CD30.
kaplan meyer
Time frame: 17/10/2022
the correlation between the molecular abnormalities and the expression of Cyclon, NPM1 and CD30
mutational signature
Time frame: 17/10/2022
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France